-
1
-
-
84910274043
-
The role of potassium in the natriuretic response to a steroidal lactone (SC-9420)
-
F.F.Taylor, W.W.Faloon The role of potassium in the natriuretic response to a steroidal lactone (SC-9420). J Clin Endocrinol Metab. 1959;19:1683–1687. doi:10.1210/jcem-19-12-1683.
-
(1959)
J Clin Endocrinol Metab
, vol.19
, pp. 1683-1687
-
-
Taylor, F.F.1
Faloon, W.W.2
-
2
-
-
84906807383
-
Four-membered ring-containing spirocycles: synthetic strategies and opportunities
-
E.M.Carreira, T.C.Fessard. Four-membered ring-containing spirocycles:synthetic strategies and opportunities. Chem Rev (Washington, DC, U S.). 2014;114:8257–8322. doi:10.1021/cr500127b.•• Important paper focused on four-membered spirocycles.
-
(2014)
Chem Rev (Washington, DC, U S.)
, vol.114
, pp. 8257-8322
-
-
Carreira, E.M.1
Fessard, T.C.2
-
4
-
-
10344242467
-
A library of spirooxindoles based on a stereoselective three-component coupling reaction
-
M.M.C.Lo, C.S.Neumann, S.Nagayama, et al. A library of spirooxindoles based on a stereoselective three-component coupling reaction. J Am Chem Soc. 2004;126:16077–16086. doi:10.1021/ja045089d.
-
(2004)
J Am Chem Soc
, vol.126
, pp. 16077-16086
-
-
Lo, M.M.C.1
Neumann, C.S.2
Nagayama, S.3
-
5
-
-
70350409235
-
The impact of aromatic ring count on compound developability: are too many aromatic rings a liability in drug design?
-
T.J.Ritchie, S.J.F.MacDonald. The impact of aromatic ring count on compound developability:are too many aromatic rings a liability in drug design? Drug Discov Today. 2009;14:1011–1020. doi:10.1016/j.drudis.2009.07.014.• Important article on the impact of aromatic ring count on developability.
-
(2009)
Drug Discov Today
, vol.14
, pp. 1011-1020
-
-
Ritchie, T.J.1
MacDonald, S.J.F.2
-
6
-
-
65649142070
-
Heteroaromatic rings of the future
-
W.R.Pitt, D.M.Parry, B.G.Perry, et al. Heteroaromatic rings of the future. J Med Chem. 2009;52:2952–2963. doi:10.1021/jm801513z.
-
(2009)
J Med Chem
, vol.52
, pp. 2952-2963
-
-
Pitt, W.R.1
Parry, D.M.2
Perry, B.G.3
-
7
-
-
84905924558
-
The use of spirocyclic scaffolds in drug discovery
-
Y.Zheng, C.M.Tice, S.B.Singh. The use of spirocyclic scaffolds in drug discovery. Bioorg Med Chem Lett. 2014;24:3673–3682. doi:10.1016/j.bmcl.2014.06.081.•• Review of recent spirocyclic scaffolds in drug discovery (2011–2014).
-
(2014)
Bioorg Med Chem Lett
, vol.24
, pp. 3673-3682
-
-
Zheng, Y.1
Tice, C.M.2
Singh, S.B.3
-
8
-
-
84879067500
-
Structure-based design of β-site APP cleaving enzyme 1 (BACE1) inhibitors for the treatment of Alzheimer’s disease
-
J.Yuan, S.Venkatraman, Y.Zheng, et al. Structure-based design of β-site APP cleaving enzyme 1 (BACE1) inhibitors for the treatment of Alzheimer’s disease. J Med Chem. 2013;56:4156–4180. doi:10.1021/jm301659n.• Important review of SBDD for BACE1.
-
(2013)
J Med Chem
, vol.56
, pp. 4156-4180
-
-
Yuan, J.1
Venkatraman, S.2
Zheng, Y.3
-
9
-
-
84918559343
-
Inhibitors of β-site amyloid precursor protein cleaving enzyme (BACE1): identification of (S)-7-(2-fluoropyridin-3-yl)-3-((3-methyloxetan-3-yl)ethynyl)-5′H-spiro[chromeno[2,3-b]pyridine-5,4′-oxazol]-2′-amine (AMG-8718)
-
T.A.Dineen, K.Chen, A.C.Cheng, et al. Inhibitors of β-site amyloid precursor protein cleaving enzyme (BACE1):identification of (S)-7-(2-fluoropyridin-3-yl)-3-((3-methyloxetan-3-yl)ethynyl)-5′H-spiro[chromeno[2,3-b]pyridine-5,4′-oxazol]-2′-amine (AMG-8718). J Med Chem. 2014;57:9811–9831. doi:10.1021/jm5012676.
-
(2014)
J Med Chem
, vol.57
, pp. 9811-9831
-
-
Dineen, T.A.1
Chen, K.2
Cheng, A.C.3
-
10
-
-
84918513804
-
8-Tetrahydropyran-2-yl chromans: highly selective beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors
-
A.A.Thomas, K.W.Hunt, B.Newhouse, et al. 8-Tetrahydropyran-2-yl chromans:highly selective beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors. J Med Chem. 2014;57:10112–10129. doi:10.1021/jm5015132.
-
(2014)
J Med Chem
, vol.57
, pp. 10112-10129
-
-
Thomas, A.A.1
Hunt, K.W.2
Newhouse, B.3
-
11
-
-
84982235705
-
Preparation of C-6 spirocarbocyclic iminothiadiazine dioxides as BACE inhibitors useful in treatment of diseases
-
Merck Sharp & Dohme Corp., USA. Preparation of C-6 spirocarbocyclic iminothiadiazine dioxides as BACE inhibitors useful in treatment of diseases. WO2015094930 (2015).
-
(2015)
WO2015094930
-
-
-
12
-
-
84946550619
-
Fatty acid amide hydrolase inhibitors: a patent review (2009-2014)
-
A.Lodola, R.Castelli, M.Mor, et al. Fatty acid amide hydrolase inhibitors:a patent review (2009-2014). Expert Opin Ther Pat. 2015;25:1247–1266. doi:10.1517/13543776.2015.1067683.• Important review of fatty acid amide hydrolase inhibitor-related patents.
-
(2015)
Expert Opin Ther Pat
, vol.25
, pp. 1247-1266
-
-
Lodola, A.1
Castelli, R.2
Mor, M.3
-
13
-
-
80054791082
-
Discovery of novel spirocyclic inhibitors of fatty acid amide hydrolase (FAAH). Part 2. Discovery of 7-azaspiro[3.5]nonane urea PF-04862853, an orally efficacious inhibitor of fatty acid amide hydrolase (FAAH) for pain
-
M.J.Meyers, S.A.Long, M.J.Pelc, et al. Discovery of novel spirocyclic inhibitors of fatty acid amide hydrolase (FAAH). Part 2. Discovery of 7-azaspiro[3.5]nonane urea PF-04862853, an orally efficacious inhibitor of fatty acid amide hydrolase (FAAH) for pain. Bioorg Med Chem Lett. 2011;21:6545–6553. doi:10.1016/j.bmcl.2011.08.048.
-
(2011)
Bioorg Med Chem Lett
, vol.21
, pp. 6545-6553
-
-
Meyers, M.J.1
Long, S.A.2
Pelc, M.J.3
-
14
-
-
84920165024
-
Decreasing the rate of metabolic ketone reduction in the discovery of a clinical acetyl-CoA carboxylase inhibitor for the treatment of diabetes
-
D.A.Griffith, D.W.Kung, W.P.Esler, et al. Decreasing the rate of metabolic ketone reduction in the discovery of a clinical acetyl-CoA carboxylase inhibitor for the treatment of diabetes. J Med Chem. 2014;57:10512–10526. doi:10.1021/jm5016022.
-
(2014)
J Med Chem
, vol.57
, pp. 10512-10526
-
-
Griffith, D.A.1
Kung, D.W.2
Esler, W.P.3
-
15
-
-
84939138677
-
Discovery of novel DNA gyrase inhibiting spiropyrimidinetriones: benzisoxazole fusion with N-linked oxazolidinone substituents leading to a clinical candidate (ETX0914)
-
G.S.Basarab, P.Doig, V.Galullo, et al. Discovery of novel DNA gyrase inhibiting spiropyrimidinetriones:benzisoxazole fusion with N-linked oxazolidinone substituents leading to a clinical candidate (ETX0914). J Med Chem. 2015;58:6264–6282. doi:10.1021/acs.jmedchem.5b00863.
-
(2015)
J Med Chem
, vol.58
, pp. 6264-6282
-
-
Basarab, G.S.1
Doig, P.2
Galullo, V.3
-
16
-
-
84955515384
-
Discovery of MK-8831, a novel spiro-proline macrocycle as a pan-genotypic HCV-NS3/4a protease inhibitor
-
S.F.Neelamkavil, S.Agrawal, T.Bara, et al. Discovery of MK-8831, a novel spiro-proline macrocycle as a pan-genotypic HCV-NS3/4a protease inhibitor. ACS Med Chem Lett. 2016;7:111–116. doi:10.1021/acsmedchemlett.5b00425.
-
(2016)
ACS Med Chem Lett
, vol.7
, pp. 111-116
-
-
Neelamkavil, S.F.1
Agrawal, S.2
Bara, T.3
-
18
-
-
0029129652
-
Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue
-
A.A.Patchett, R.P.Nargund, J.R.Tata, et al. Design and biological activities of L-163,191 (MK-0677):a potent, orally active growth hormone secretagogue. Proc Natl Acad Sci U S A. 1995;92:7001–7005.
-
(1995)
Proc Natl Acad Sci U S A
, vol.92
, pp. 7001-7005
-
-
Patchett, A.A.1
Nargund, R.P.2
Tata, J.R.3
-
19
-
-
84982203121
-
-
Available from:, May
-
Phase 2 clinical trials of MK-1602. [cited 2016 May15]. Available from: https://clinicaltrials.gov/ct2/results?term=MK-1602&pg=1
-
Phase 2 clinical trials of MK-1602
-
-
-
20
-
-
84907794133
-
Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine
-
I.M.Bell. Calcitonin gene-related peptide receptor antagonists:new therapeutic agents for migraine. J Med Chem. 2014;57:7838–7858. doi:10.1021/jm500364u.
-
(2014)
J Med Chem
, vol.57
, pp. 7838-7858
-
-
Bell, I.M.1
-
21
-
-
84940613588
-
Role of rolapitant in chemotherapy-induced emesis
-
I.Olver. Role of rolapitant in chemotherapy-induced emesis. Lancet Oncol. 2015;16:1006–1007. doi:10.1016/S1470-2045(15)00096-0.
-
(2015)
Lancet Oncol
, vol.16
, pp. 1006-1007
-
-
Olver, I.1
-
22
-
-
79953732945
-
Molecular imaging of σ receptors: synthesis and evaluation of the potent σ1 selective radioligand [18F]fluspidine
-
S.Fischer, C.Wiese, E.Grosse Maestrup, et al. Molecular imaging of σ receptors:synthesis and evaluation of the potent σ1 selective radioligand [18F]fluspidine. Eur J Nucl Med Mol Imaging. 2011;38:540–551. doi:10.1007/s00259-010-1658-z.
-
(2011)
Eur J Nucl Med Mol Imaging
, vol.38
, pp. 540-551
-
-
Fischer, S.1
Wiese, C.2
Grosse Maestrup, E.3
-
23
-
-
84962185125
-
Discovery of (3-(4-(2-oxa-6-azaspiro[3.3]heptan-6-ylmethyl)phenoxy)azetidin-1-yl)(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)methanone (AZD1979), a melanin concentrating hormone receptor 1 (MCHr1) antagonist with favorable physicochemical properties
-
A.Johansson, C.Löfberg, M.Antonsson, et al. Discovery of (3-(4-(2-oxa-6-azaspiro[3.3]heptan-6-ylmethyl)phenoxy)azetidin-1-yl)(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)methanone (AZD1979), a melanin concentrating hormone receptor 1 (MCHr1) antagonist with favorable physicochemical properties. J Med Chem. 2016;59:2497–2511. doi:10.1021/acs.jmedchem.5b01797.
-
(2016)
J Med Chem
, vol.59
, pp. 2497-2511
-
-
Johansson, A.1
Löfberg, C.2
Antonsson, M.3
-
24
-
-
84896295869
-
Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection
-
J.O.Link, J.G.Taylor, L.Xu, et al. Discovery of ledipasvir (GS-5885):a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. J Med Chem. 2014;57:2033–2046. doi:10.1021/jm401499g.
-
(2014)
J Med Chem
, vol.57
, pp. 2033-2046
-
-
Link, J.O.1
Taylor, J.G.2
Xu, L.3
-
25
-
-
84896308812
-
Discovery and development of hepatitis C virus NS5A replication complex inhibitors
-
M.Belema, O.D.Lopez, J.A.Bender, et al. Discovery and development of hepatitis C virus NS5A replication complex inhibitors. J Med Chem. 2014;57:1643–1672. doi:10.1021/jm401793m.
-
(2014)
J Med Chem
, vol.57
, pp. 1643-1672
-
-
Belema, M.1
Lopez, O.D.2
Bender, J.A.3
-
26
-
-
84908148515
-
SAR405838: an optimized inhibitor of MDM2–p53 interaction that induces complete and durable tumor regression
-
S.Wang, W.Sun, Y.Zhao, et al. SAR405838:an optimized inhibitor of MDM2–p53 interaction that induces complete and durable tumor regression. Cancer Res. 2014;74:5855–5865. doi:10.1158/0008-5472.CAN-14-0799.
-
(2014)
Cancer Res
, vol.74
, pp. 5855-5865
-
-
Wang, S.1
Sun, W.2
Zhao, Y.3
-
27
-
-
84866336965
-
Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes
-
Y.Ohtake, T.Sato, T.Kobayashi, et al. Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem. 2012;55:7828–7840. doi:10.1021/jm300884k.
-
(2012)
J Med Chem
, vol.55
, pp. 7828-7840
-
-
Ohtake, Y.1
Sato, T.2
Kobayashi, T.3
-
28
-
-
84982235711
-
Boehringer Ingelheim International GmbH. Preparation of spirocyclic azoles and azines as inhibitors of β-secretase (BACE)
-
Vitae Pharmaceuticals, Inc., USA. Boehringer Ingelheim International GmbH. Preparation of spirocyclic azoles and azines as inhibitors of β-secretase (BACE). WO2010105179 (2010).
-
(2010)
WO2010105179
-
-
|